News headlines about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cardiome Pharma earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.1197913562376 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Cardiome Pharma stock traded down $0.05 during trading hours on Friday, reaching $2.29. The stock had a trading volume of 53,638 shares, compared to its average volume of 133,670. The company has a market cap of $81.59, a P/E ratio of -2.54 and a beta of 0.22. Cardiome Pharma has a twelve month low of $1.29 and a twelve month high of $4.84. The company has a debt-to-equity ratio of 2.47, a quick ratio of 3.99 and a current ratio of 4.80.
Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.94 million. Cardiome Pharma had a negative return on equity of 123.36% and a negative net margin of 124.17%. equities research analysts forecast that Cardiome Pharma will post -0.77 EPS for the current year.
Cardiome Pharma Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.